- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06749457
Um estudo para avaliar a segurança e farmacocinética do AZD7760 em adultos saudáveis (fase I) e adultos com doença renal em estágio terminal em hemodiálise com cateter venoso central (fase IIa) (PEAK)
Um estudo de fase I/IIa randomizado, duplo-cego e controlado por placebo para avaliar a segurança e a farmacocinética de AZD7760 em participantes saudáveis e em pacientes com doença renal em estágio terminal recebendo hemodiálise por meio de um cateter venoso central
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis through a central venous catheter (Phase IIa).
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
In the Phase I portion of the study, participants will be randomized to receive one of 3 dosages of AZD7760 or placebo as a single intravenous infusion.
Study details include:
- A 28-day Screening Period.
- A Dosing Period of 3 days in which a single intravenous infusion will be given on Day 1.
- A Follow-up Period of 12 months from the time of administration of the study intervention.
In the Phase IIa portion of the study, participants will be randomized to receive either AZD7760 or placebo as 2 intravenous infusions given 3 months apart.
Study details include:
- A 28-day Screening Period.
- A Dosing Period in which 2 intravenous infusions will be given 3 months apart (Day 1 and Day 91).
- A Follow-up Period of 12 months after the last administration of the study intervention on Day 91.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Alabama
-
Huntsville, Alabama, Estados Unidos, 35805
- Research Site
-
-
California
-
Chula Vista, California, Estados Unidos, 91910
- Research Site
-
Glendale, California, Estados Unidos, 91206
- Research Site
-
Granada Hills, California, Estados Unidos, 91344
- Research Site
-
Los Angeles, California, Estados Unidos, 90027
- Research Site
-
Northridge, California, Estados Unidos, 91324
- Research Site
-
Northridge, California, Estados Unidos, 91325
- Research Site
-
Oxnard, California, Estados Unidos, 93036
- Research Site
-
Riverside, California, Estados Unidos, 92503
- Research Site
-
San Dimas, California, Estados Unidos, 91773
- Research Site
-
Tarzana, California, Estados Unidos, 91356
- Research Site
-
Valencia, California, Estados Unidos, 91355
- Research Site
-
Victorville, California, Estados Unidos, 92392
- Research Site
-
-
Colorado
-
Englewood, Colorado, Estados Unidos, 80110
- Research Site
-
-
Florida
-
Bradenton, Florida, Estados Unidos, 34209
- Research Site
-
Coral Springs, Florida, Estados Unidos, 33071
- Research Site
-
Hollywood, Florida, Estados Unidos, 33024
- Research Site
-
Orlando, Florida, Estados Unidos, 32806
- Research Site
-
Tampa, Florida, Estados Unidos, 33603
- Research Site
-
-
Georgia
-
Lawrenceville, Georgia, Estados Unidos, 30046
- Research Site
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60640
- Research Site
-
Chicago, Illinois, Estados Unidos, 60643
- Research Site
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- Research Site
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40503
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21225
- Research Site
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48202
- Research Site
-
Pontiac, Michigan, Estados Unidos, 48341
- Research Site
-
-
Mississippi
-
Tupelo, Mississippi, Estados Unidos, 38801
- Research Site
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64111
- Research Site
-
-
Nebraska
-
Lincoln, Nebraska, Estados Unidos, 68510
- Research Site
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89128
- Research Site
-
-
New Jersey
-
Jersey City, New Jersey, Estados Unidos, 07305
- Research Site
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87109
- Research Site
-
-
New York
-
Ridgewood, New York, Estados Unidos, 11385
- Research Site
-
-
North Carolina
-
Winston-Salem, North Carolina, Estados Unidos, 27103
- Research Site
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Estados Unidos, 18017
- Research Site
-
-
Texas
-
Beaumont, Texas, Estados Unidos, 77706
- Research Site
-
Dallas, Texas, Estados Unidos, 75246
- Research Site
-
Houston, Texas, Estados Unidos, 77074
- Research Site
-
McAllen, Texas, Estados Unidos, 78503
- Research Site
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Phase I:
- Participant must be 18 to 55 years of age (inclusive), at the time of signing the informed consent.
- Body weight ≥ 45 kilograms (kg) and ≤ 110 kg and Body Mass Index (BMI) within the range ≥ 18.0 to ≤ 30.0 kilograms per square meter (kg/m2) (inclusive) at screening.
- Healthy participants with no clinically significant concomitant diseases or medications (except for those specifically permitted by the protocol) according to medical history, physical examination, screening safety laboratory tests, and screening parameters, as per the judgement of the investigator.
Phase IIa:
-
Participant must be ≥ 18 years of age at the time of signing the informed consent.
-
Participants who meet all of the following disease status requirements:
- Diagnosed with End-stage kidney disease (ESKD).
- Requiring hemodialysis through a tunneled central venous catheter as the primary vascular access for hemodialysis.
- Receiving hemodialysis for treatment of ESKD for at least 60 days before randomization.
- At least 3 previous dialysis sessions using current dialyzer.
- Receiving adequate hemodialysis based on a single-pool Kt/V measurement > 1.2 within the last 30 days.
- No new medications have been added to the participant's regimen in the last 2 weeks prior to dosing. 'New medication' is defined as any medication that has not been prescribed or used by the participant previously (including formulation changes). Medication previously prescribed or used by the participant with dose adjustments is allowed and not considered as new medication for the purpose of this study.
- Not taking long-term systemic antibiotics with activity against S aureus.
Exclusion Criteria:
Phase I:
- Known hypersensitivity to any component of the study intervention
- Previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of monoclonal antibodies (mAbs).
- Clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following intramuscular injections or venipuncture.
- Aspartate Aminotransferase (AST) or alanine Aminotransferase (ALT) above 1.5 × upper limit of normal (ULN) at screening. Testing may be repeated once at the investigator's discretion.
- Estimated glomerular filtration rate < 90 mL/min/1.73 m2 calculated using the Chronic Kidney Disease Epidemiology Collaboration equation at screening.
- Hemoglobin or platelet count below the lower limit of normal at screening. Testing may be repeated once at the investigator's discretion.
- White blood cell counts outside normal reference ranges unless judged by the investigator to be out of range given the known variation in white blood cell count reference interval by ethnicity. Testing may be repeated once at the investigator's discretion.
- History of malignancy other than treated non-melanoma skin cancers or locally treated cervical cancer in the previous 5 years.
- Any laboratory value in the screening panel that, in the opinion of the investigator, is clinically significant or might confound analysis of study results. Testing may be repeated once at the investigator's discretion.
- Any clinically significant abnormalities on 12-lead electrocardiogram (ECG) at screening, as judged by the investigator.
- Acute (time-limited) illness, including fever ≥ 38 °C (100.4 °F), one day prior to or on day of planned dosing; participants excluded for transient acute illness may be dosed if illness resolves within the 28-day Screening Period or may be rescreened once.
- Known or suspected congenital or acquired immunodeficiency, or receipt of immunosuppressive therapy, including any course of glucocorticoid therapy exceeding 2 weeks of prednisone or equivalent at a dose of 20 mg daily or every other day within 6 months prior to screening.
- Any condition that has the potential to increase clearance of the study intervention (eg, protein loss conditions such as severe enteropathies, or plasmapheresis).
- Blood drawn in excess of a total of 450 milliliters (mL) (1 unit) for any reason within 2 months prior to screening.
- Absence of suitable veins for blood sampling and administration of study intervention.
- Any other condition that would compromise safety of the participants.
- Any condition that, in the opinion of the investigator, might interfere with evaluation of the study intervention or interpretation of participant safety or study results.
Phase IIa:
-
Known hypersensitivity to any component of the study intervention.
-
History of allergic disease or reactions likely to be exacerbated by any component of the study intervention as listed in dose formulation section.
-
Previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of mAbs.
-
Hemoglobin < 9 g/dL at screening considered by the investigator to be due to acute condition(s). Testing may be repeated once at the investigator's discretion.
-
Serum albumin of < 3 g/dL at screening considered by the investigator to be due to acute condition(s). Testing may be repeated once at the investigator's discretion.
-
Myocardial infarction, acute coronary syndrome, stroke, seizure, or a thrombotic/thromboembolic event (eg, deep vein thrombosis or pulmonary embolism, but excluding vascular access thrombosis) within 90 days prior to randomization.
-
Known S aureus infection within 90 days of study entry.
-
Known acute viral or bacterial infection or symptoms/signs consistent with such an infection within the 21 days prior to infusion or study intervention. Mild intercurrent viral illness with a temperature of 38.1 °C (100.6 °F) or less does not require exclusion, if in the judgement of the investigator this illness will not interfere with the evaluation of the mAb.
-
Participants with malignancy undergoing chemotherapy.
-
Scheduled date for living donor kidney transplant.
-
Plans to switch to peritoneal dialysis within the primary endpoint time period (181 days).
-
Regarding arteriovenous fistula (AVF) or arteriovenous graft (AVG):
(a) Future AVG or AVG: (i) Participants with central venous catheters currently in use for dialysis, and future plans for AVF or AVG use within 90 days of randomization are not eligible.
(ii) Participants with central venous catheters currently in use for dialysis, and future plans for AVF or AVG placement, but no plans for AVF or AVG use within 90 days of randomization are eligible.
(b) Existing AVG or AVG: (i) Participants with central venous catheters in use for dialysis, but also with an existing AVF or AVG that is not in use and with no future plans for use are eligible.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Phase I: AZD7760 Dose A
Participants will receive a single dose of AZD7760 Dose A intravenously on Day 1. |
Participants will receive AZD7760 as a single intravenous infusion. |
|
Experimental: Phase I: AZD7760 Dose B
Participants will receive a single dose of AZD7760 Dose B intravenously on Day 1. |
Participants will receive AZD7760 as a single intravenous infusion. |
|
Experimental: Phase I: AZD7760 Dose C
Participants will receive a single dose of AZD7760 Dose C intravenously on Day 1. |
Participants will receive AZD7760 as a single intravenous infusion. |
|
Comparador de Placebo: Phase I: Placebo
Participants will receive a single dose of placebo on Day 1. |
Participants will be administered placebo through intravenous infusion. |
|
Experimental: Phase IIa: AZD7760 Dose D and Placebo
Participants will receive AZD7760 Dose D and placebo on Day 1 on Day 91. |
Participants will receive AZD7760 as a single intravenous infusion. Participants will be administered placebo through intravenous infusion. |
|
Experimental: Phase IIa: AZD7760 Dose E
Participants will receive AZD7760 Dose E on Day 1 and Day 91. |
Participants will receive AZD7760 as a single intravenous infusion. |
|
Comparador de Placebo: Phase IIa: Placebo
Participants will receive placebo on Day 1 and on Day 91. |
Participants will be administered placebo through intravenous infusion. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Phase I: Occurence of adverse events (AEs)
Prazo: Day 1 to Day 181
|
To evaluate the safety of AZD7760 administered as a single intravenous (IV) Dose A, B, or C. |
Day 1 to Day 181
|
|
Phase I: Occurence of medically-attended adverse events (MAAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs)
Prazo: Day 1 to Day 361
|
To evaluate the safety of AZD7760 administered as a single IV Dose A, B, or C. |
Day 1 to Day 361
|
|
Phase IIa: Occurrence of AEs, MAAEs, SAEs, and AESIs
Prazo: Day 1 to Day 181
|
To evaluate the safety of AZD7760 compared with placebo as:
|
Day 1 to Day 181
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Phase I: Maximum observed plasma (peak) drug concentration (Cmax)
Prazo: Day 1 to Day 361
|
To characterize the pharmacokinetics (PK) of AZD7760 in serum. |
Day 1 to Day 361
|
|
Phase I: Time to reach peak or maximum observed concentration following drug administration (tmax)
Prazo: Day 1 to Day 361
|
To characterize the PK of AZD7760 in serum. |
Day 1 to Day 361
|
|
Phase I: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz)
Prazo: Day 1 to Day 361
|
To characterize the PK of AZD7760 in serum. |
Day 1 to Day 361
|
|
Phase I: Area under the plasma concentration-curve from zero to the last quantifiable concentration (AUClast)
Prazo: Day 1 to Day 361
|
To characterize the PK of AZD7760 in serum. |
Day 1 to Day 361
|
|
Phase I: Area under plasma concentration-time curve from zero extrapolated to infinity (AUCinf)
Prazo: Day 1 to Day 361
|
To characterize the PK of AZD7760 in serum. |
Day 1 to Day 361
|
|
Phase I: Apparent volume of distribution at steady state (Vss)
Prazo: Day 1 to Day 361
|
To characterize the PK of AZD7760 in serum. |
Day 1 to Day 361
|
|
Phase I: Apparent volume of distribution at the terminal phase (Vz)
Prazo: Day 1 to Day 361
|
To characterize the PK of AZD7760 in serum. |
Day 1 to Day 361
|
|
Phase I: Incidence of ADA
Prazo: Day 1 to Day 361
|
To evaluate ADA responses to AZD7760 in serum. |
Day 1 to Day 361
|
|
Phase IIa: Cmax
Prazo: Day 1 to Day 181 and Day 1 to Day 451
|
To characterize the serum PK profiles of AZD7760 administered as:
|
Day 1 to Day 181 and Day 1 to Day 451
|
|
Phase IIa: tmax
Prazo: Day 1 to Day 181 and Day 1 to Day 451
|
To characterize the serum PK profiles of AZD7760 administered as:
|
Day 1 to Day 181 and Day 1 to Day 451
|
|
Phase IIa: t1/2λz
Prazo: Day 1 to Day 181 and Day 1 to Day 451
|
To characterize the serum PK profiles of AZD7760 administered as:
|
Day 1 to Day 181 and Day 1 to Day 451
|
|
Phase IIa: AUClast
Prazo: Day 1 to Day 181 and Day 1 to Day 451
|
To characterize the serum PK profiles of AZD7760 administered as:
|
Day 1 to Day 181 and Day 1 to Day 451
|
|
Phase IIa: AUCinf
Prazo: Day 1 to Day 181 and Day 1 to Day 451
|
To characterize the serum PK profiles of AZD7760 administered as:
|
Day 1 to Day 181 and Day 1 to Day 451
|
|
Phase IIa: Vss
Prazo: Day 1 to Day 181 and Day 1 to Day 451
|
To characterize the serum PK profiles of AZD7760 administered as:
|
Day 1 to Day 181 and Day 1 to Day 451
|
|
Phase IIa: Vz
Prazo: Day 1 to Day 181 and Day 1 to Day 451
|
To characterize the serum PK profiles of AZD7760 administered as:
|
Day 1 to Day 181 and Day 1 to Day 451
|
|
Phase IIa: Incidence of anti-drug antibodies (ADAs) to AZD7760 in serum
Prazo: Day 1 to Day 181 and Day 1 to Day 451
|
To evaluate ADA responses to AZD7760 administered as:
|
Day 1 to Day 181 and Day 1 to Day 451
|
|
Phase IIa: Occurrence of AEs
Prazo: Day 1 to Day 181
|
To evaluate the safety to Day 181 of AZD7760 administered as:
|
Day 1 to Day 181
|
|
Phase IIa: Occurrence of MAAEs, SAEs, and AESIs
Prazo: Day 1 to Day 451
|
To evaluate the safety to Day 451 of AZD7760 administered as:
|
Day 1 to Day 451
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Processos Patológicos
- Doenças Urogenitais Masculinas
- Doenças renais
- Doenças Urológicas
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Doença crônica
- Atributos da doença
- Infecções
- Síndrome da Resposta Inflamatória Sistêmica
- Inflamação
- Insuficiência renal
- Infecções por Bactérias Gram-Positivas
- Infecções bacterianas
- Infecções Bacterianas e Micoses
- Insuficiência Renal Crônica
- Condições Patológicas, Sinais e Sintomas
- Infecções Estafilocócicas
- Sepse
- Insuficiência Renal Crônica
Outros números de identificação do estudo
- D7480C00001
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Prazo de Compartilhamento de IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Critérios de acesso de compartilhamento IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .